Liminatus Pharma Seeks Shareholder Approval for 1-for-50 Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

Liminatus Pharma is seeking shareholder approval for a reverse stock split of up to 1-for-50 shares, a critical measure aimed at increasing its stock price to meet Nasdaq's minimum bid requirements and avoid delisting.

check_boxKey Events · Corporate Governance and Compliance · LIMN

• Reverse Stock Split Proposal

  Shareholders will vote on authorizing the Board of Directors to approve a reverse stock split of up to 1-for-50 shares, with the exact ratio to be determined by the Board.

• Nasdaq Delisting Threat

  The primary purpose of the reverse split is to regain compliance with Nasdaq's $1 minimum bid price rule, following a delisting notice received on January 15, 2026, with a compliance deadline of July 14, 2026.

• Significant Share Reduction

  If approved at a 1-for-50 ratio, the number of outstanding common shares would be reduced from approximately 50.6 million to about 1.01 million. Fractional shares will be rounded up.

• Board Discretion on Ratio and Timing

  The Board will have discretion to determine the final reverse split ratio (up to 1-for-50) and the effective date, if the proposal is approved by shareholders.

auto_awesomeAnalysis · LIMN · Life Sciences

This preliminary proxy statement reveals Liminatus Pharma's critical proposal to shareholders for a reverse stock split of up to 1-for-50 shares. This drastic measure is explicitly aimed at increasing the per-share price to meet Nasdaq's minimum bid requirements and avoid delisting. Given the company's recent 10-Q filing reiterating substantial doubt about its ability to continue as a going concern and a formal Nasdaq delisting notice received in May, this proposal is a high-stakes attempt to maintain its exchange listing. Failure to approve could force the stock to trade on less liquid over-the-counter markets, severely impacting investor confidence and access to capital.